TOULOUSE, France & LAKELAND, Mich.--(BUSINESS WIRE)--Regulatory News:
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, announces that all resolutions were voted in accordance with the recommendations of the Board of Directors.
The Meeting renewed the mandate of Emmanuel HUYNH, who remains Chairman of the Board of Directors and a member of the Audit and Compensation Committees, as well as of the Scientific, Research and Patents Committee. Cyrille Tupin's mandate as Director and Chief Executive Officer is also renewed.
To date, the Board of Directors of ABIONYX Pharma is composed of:
– Emmanuel HUYNH, Chairman of the Board of Directors
– Cyrille TUPIN, Chief Executive Officer
– Karen Noël
– Laura Coruzzi
– Christian Chavy
– Bpifrance Participations, represented by Olivier Martinez, censor
The General Meeting also approved the share buyback program and the continuation of the liquidity contract.
The minutes of the General Meeting and the results of the votes by resolution are available on the Company's website in the General Meetings section.
Next financial press release: Cash position and activity update for Q2 2022, August 18, 2022
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to contribute to health through innovative therapies in indications where there is no effective or existing treatment, even the rarest ones. Thanks to its partners in research, medicine, biopharmaceuticals and shareholding, the company innovates on a daily basis to propose drugs for the treatment of renal and ophthalmological diseases, or new HDL vectors used for targeted drug delivery.